


LEGEND-T2DM Evidence Dissemination Summary

Target: **sitagliptin**, Comparator: **dapagliflozin** Outcome: **Hospitalization with heart failure**

How Often? (Incidence rates in the PS-matched target cohorts)

| Data source | Persons exposed | Person-time (yrs) | Persons with outcome | IR (/1,000 PY) |
|---------------------|-----------------|-------------------|----------------------|----------------|
| IQVIA DA Germany | 17,552 | 18,535 | 0 | 0.00 |
| IQVIA LDP France | - | - | - | - |
| IQVIA Open Claims | 599,165 | 531,197 | 5,318 | 10.01 |
| Merative CCAE | 45,636 | 37,858 | 201 | 5.31 |
| Merative MDCCD | 6,225 | 4,227 | 100 | 23.66 |
| Merative MDCR | 6,857 | 5,601 | 163 | 29.10 |
| Optum Clinformatics | 23,149 | 18,207 | 523 | 28.73 |
| Optum EHR | 55,752 | 26,473 | 370 | 13.98 |
| Veterans Affairs | - | - | - | - |

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

